Work

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors

Year: 2013

Type: article

Abstract: Acquired resistance to imatinib is a significant problem for the clinical management of gastrointestinal stromal tumor (GIST) patients, and second-line small molecules have shown limited efficacy in this setting. We have recently demonstrated that a monoclonal antibody targeting KIT could potentially bypass imatinib resistance in preclinical models of GIST.

Source: OncoImmunology

DOI: 10.4161/onci.24452

Authors: Badreddin Edris, Stephen Willingham, Kipp Weiskopf, Anne K Volkmer, Jens-Peter Volkmer, Thomas Mühlenberg, Irving L Weissman, Matt van de Rijn

Institutions: Stanford Medicine, Stanford University, Institute for Stem Cell Biology and Regenerative Medicine, Institute for Stem Cell Biology and Regenerative Medicine, University of Duisburg-Essen

Language: English

Topic: Gastrointestinal Tumor Research and Treatment

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,913

Funder: National Cancer Institute

Award: G5808353900

OpenAlex ID: W1980194317

FWCI: 0.946

Cites: 10

Cited by: 6

Related to: 10